Novo Nordisk manufactures and markets pharmaceutical products and services and was created in 1989 through a merger of two Danish companies dating back to the 1920s. It produces, in particular, diabetes care equipment and medications. Novo Nordisk is also involved with haemostasis management, growth hormone therapy and hormone replacement therapy.
Corporate Knights announced its eighth annual Global 100 list of the most sustainable large corporations in the world. The Global 100 is a leading sustainability ranking and the number one ranked company is considered by many the most sustainable company in the world. In 2012 it was Novo Nordisk, the Danish pharmaceutical firm.
Novo Nordisk is on record proclaiming that access to essential medicines is a human right, and it sells human insulin (the most basic kind) to 33 of the world’s poorest countries at no more than 20 percent of the average price in the western world. Their sustainability report has been integrated, since 2004, into their annual report. The company ceased the practice of using live animals for quality testing of existing products.
Entering into 2012, Novo Nordisk was cited by Forbes magazine as ‘The most sustainable company on Earth’. A prestigious position, hard-earned and tough to defend.
Novo Nordisk sells its products in more than 180 countries. Among them are the richest and poorest countries in
the world, with healthcare systems ranging from well-developed to non- existent. And yet, Novo Nordisk’s basic business model and strategy is the same in all countries.
In 1994, Novo Nordisk became the first company in Denmark, and one of the first in the world, to publish an environmental report. Five years later, the company published its first social report. In 2004, Novo Nordisk became the third company to publish an integrated financial, environmental, and social report.
The company believes that a healthy economy, environment and society is fundamental to long-term business success. This is why they manage their business in accordance with the Triple Bottom Line (TBL) business principle and pursue business solutions that maximise value to our stakeholders as well as our shareholders.
Headquartered in Denmark, Novo Nordisk employs approximately 34,700 employees in 75 countries, and markets its products in 180 countries.
U.S. regulators refused to approve Novo Nordisk's new long-acting insulin Tresiba until it conducts extra tests for potential heart risks, dealing a major blow to a key product for the Danish drugmaker.
As the world suffers from an epidemic of type 2 diabetes tied to over-eating and lack of exercise, demand for treatments has snowballed. Novo has benefited more than any other company because it is so focused on diabetes, lifting its shares to a lofty premium over other European drugmakers.
Novo Nordisk is a global healthcare company with 89 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.